Lilly Says Safety Not A Factor In Dropping Lupus Development With Olumiant

 
• By Joseph Haas
  
Indianapolis - Circa April 2016: Eli Lilly and Company World Headquarters. Lilly makes Medicines and Pharmaceuticals IV - Image
Lilly may be backing away from label expansion plans for Olumiant in atopic dermatitis
Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Strategy

More from Business